Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.
Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.
复制标题
DOI：
10.18632/oncotarget.23872
复制
发表时间：
2018-01-23
期刊：
影响因子：
--
通讯作者：
Kobayashi, Takashi
中科院分区：
文献类型：
--
作者：
Masuda, Norihiko;Ogawa, Osamu;Kobayashi, Takashi
正如多项病例对照研究报告的那样，一种基于尿液的10项膀胱癌（BCa）诊断标志物有潜力无创性地预测高危患者中膀胱癌的存在。本荟萃分析旨在重新评估并证明基于尿液的10项诊断检测在诊断应用中的稳健性和一致性。我们重新分析了之前五项已发表的关于10项诊断检测的病例对照研究中收集的原始数据。这些研究报告了十种尿蛋白生物标志物用于检测膀胱癌的敏感性和特异性，包括白细胞介素8、基质金属蛋白酶9和10、血管生成素、载脂蛋白E、多配体聚糖1、α - 1抗胰蛋白酶、纤溶酶原激活物抑制剂 - 1、碳酸酐酶9和血管内皮生长因子A。数据由两名研究人员独立提取和审核。计算对数比值比（ORs）以确定10项生物标志物组合以及单个生物标志物与膀胱癌存在的关联强度。对来自1173名患者的数据进行了分析。在我们对整个队列的荟萃分析中，与对单个队列的每次分析相比，每种生物标志物的对数OR提高了1.5或更多，且95%置信区间更小。十种生物标志物的组合显示出比任何单一生物标志物更高的对数OR（对数OR：3.46，95%置信区间：2.60 - 4.31），无论肿瘤的组织学分级或疾病分期如何。我们得出结论，与任何单一生物标志物相比，与膀胱癌相关的10项诊断标志物在识别膀胱癌方面显示出更高的潜力。我们的结果证明基于10项蛋白质的诊断标志物朝着临床应用进一步发展是合理的。
A 10-plex urine-based bladder cancer (BCa) diagnostic signature has the potential to non-invasively predict the presence of BCa in at-risk patients, as reported in various case-control studies. The present meta-analysis was performed to re-evaluate and demonstrate the robustness and consistency of the diagnostic utility of the 10-plex urine-based diagnostic assay. We re-analyzed primary data collected in five previously published case-control studies on the 10-plex diagnostic assay. Studies reported the sensitivity and specificity of ten urinary protein biomarkers for the detection of BCa, including interleukin 8, matrix metalloproteinases 9 and 10, angiogenin, apolipoprotein E, syndecan 1, alpha-1 antitrypsin, plasminogen activator inhibitor-1, carbonic anhydrase 9, and vascular endothelial growth factor A. Data were extracted and reviewed independently by two investigators. Log odds ratios (ORs) were calculated to determine how strongly the 10-plex biomarker panel and individual biomarkers are associated with the presence of BCa. Data pooled from 1,173 patients were analyzed. The log OR for each biomarker was improved by 1.5 or greater with smaller 95% CI in our meta-analysis of the overall cohort compared with each analysis of an individual cohort. The combination of the ten biomarkers showed a higher log OR (log OR: 3.46, 95% CI: 2.60-4.31) than did any single biomarker irrespective of histological grade or disease stage of tumors. We concluded that the 10-plex BCa-associated diagnostic signature demonstrated a higher potential to identify BCa when compared to any single biomarker. Our results justify further advancement of the 10-plex protein-based diagnostic signature toward clinical application.